Alpine Immune Sciences Inc(ALPN) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company. The company is headquartered in Seattle, Washington and currently employs 48 full-time employees. The vlgD platform is designed to interact with multiple targets, including many present in the immune synapse. The vlgDs are developed using a process known as directed evolution. The vlgD platform exploits both known and unknown interactions at immune synapse through a process called direct evolution for patients living with cancer, autominnue/inflammatory conditions and chronic infectious disease. The company optimizes native immune system proteins for use as therapeutics. The firm also developed Transmembrane Immunomodulatory Protien (TIP) technology, based on the vIgD platform, to enhance engineered cellular therapies. TIP program is created to help companies focused on engineered cellular therapies.

Current Price

$12.00

RSI

45.960

Beta:

1.677959

November 12, 2020
22.3M
-5.5M

561.938 %
91.545 %
46.519 %
39.027 %

$1,740,000
$705,000
$1,731,000
$0
$492,000
$0
146.809 %
-145.532 %
100.000 %
-Infinity %
0.000 %

$-41,852,000
$-36,853,000
$-7,983,000
$-31,463,000
$-22,818,000
$-15,036,012
-11.944 %
-78.338 %
294.125 %
-27.477 %
-34.105 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.